How should a patient be transitioned from valsartan to sacubitril‑valsartan?

Transitioning from Valsartan to Sacubitril-Valsartan

When switching from valsartan (or any ARB) to sacubitril-valsartan, you can make the transition immediately without any washout period—simply stop the valsartan and start sacubitril-valsartan the next day. This is fundamentally different from switching from an ACE inhibitor, which requires a mandatory 36-hour washout to prevent angioedema 1, 2, 3.

Key Distinction: No Washout Required for ARB-to-ARNI Switch

The critical safety consideration is only for ACE inhibitor transitions—a strict 36-hour washout must be observed when switching from an ACE inhibitor to avoid the risk of angioedema 1, 2, 3. However, this washout is NOT required when switching from an ARB like valsartan 2.

Starting Dose Selection

Your starting dose of sacubitril-valsartan depends on the patient's current valsartan dose 2:

High-Dose ARB Patients

• If the patient is on valsartan 160 mg total daily dose (or therapeutically equivalent dose of another ARB):
  • Start sacubitril-valsartan 49/51 mg twice daily 2

Low- or Medium-Dose ARB Patients

• If the patient is on valsartan <160 mg total daily dose:
  • Start sacubitril-valsartan 24/26 mg twice daily 2, 3
  • This lower starting dose applies equally to patients who are ARB-naive or on low doses 3

Special Populations Requiring Lower Starting Dose (24/26 mg twice daily)

• Severe renal impairment (eGFR <30 mL/min/1.73 m²) 2
• Moderate hepatic impairment (Child-Pugh Class B) 2
• Elderly patients (age ≥75 years) 2
• Systolic blood pressure <100 mmHg 2

Titration Strategy

Double the dose every 2-4 weeks to reach the target maintenance dose of 97/103 mg twice daily, as tolerated 1, 3. Both condensed (3-week) and conservative (6-week) titration approaches are similarly tolerated, though gradual titration maximizes achievement of target dose in patients previously on low-dose ACE inhibitors or ARBs 2.

Monitoring Requirements

After initiation or dose increase, assess the following within 1-2 weeks 2:

• Blood pressure (watch for hypotension—a common side effect)
• Renal function (serum creatinine/eGFR)
• Serum potassium

A decrease in eGFR >30% or development of hyperkalemia should prompt dose reduction, though short-term eGFR changes don't predict long-term adverse outcomes 2.

Common Pitfalls to Avoid

1. Don't unnecessarily delay the switch: Unlike ACE inhibitors, ARBs can be stopped and sacubitril-valsartan started immediately 2

2. Don't wait for aldosterone antagonist therapy: Lack of aldosterone antagonist treatment should NOT delay initiating or switching to sacubitril-valsartan 2

3. Don't start too high in vulnerable patients: Patients on low-dose ARBs, elderly patients, those with renal/hepatic impairment, or low blood pressure need the 24/26 mg starting dose 2, 3

4. Don't forget volume status: Ensure patients are not volume-depleted before initiation, as up to 25% may develop hypotension 2

5. Screen for contraindications: History of angioedema (with or without prior ACE inhibitor/ARB use) is an absolute contraindication 1, 2

Clinical Context

The evidence strongly supports this transition strategy. Sacubitril-valsartan reduces cardiovascular death and heart failure hospitalization by 20% compared to enalapril in the PARADIGM-HF trial 1, and real-world data demonstrate successful switching in 89% of patients with incremental improvements in functional status, ejection fraction, and quality of life 4. The medication can even be initiated de novo without prior ACE inhibitor or ARB exposure, demonstrating its safety profile 2.

Monitor closely for hypotension (most common adverse effect), hyperkalemia, and worsening renal function, but these should not prevent appropriate initiation in eligible patients with heart failure with reduced ejection fraction.